Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas.
Extracellular matrix metalloproteinase inducer (EMMPRIN), a member of the immunoglobulin superfamily, is present on the surface of tumor cells where it stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPs). We have analyzed the clinicopathological characteristics of EMMPRIN and MMP2 expression in normal brain tissue and pediatric gliomas and evaluated their prognostic value in diagnosing the latter. Immunochemistry analysis revealed EMMPRIN and MMP2 expression in cryo-sections of pediatric gliomas (45 samples) and normal brain tissue (20 samples). Both EMMPRIN and MMP2 were expressed in normal brain and glioma tissues with different levels of malignancy. The intensively positive expression rates of EMMPRIN (22/27) and MMP2 (21/27) in anaplastic astrocytoma and glioblastoma tissues were significantly higher than those in normal brain and low-grade astrocytoma tissues (2/28 and (1/2)8, respectively). Spearman analysis indicated that the expression level of EMMPRIN was significantly positively correlated with that of MMP2 (r = 0.86, p < 0.01). The positive expression of EMMPRIN and MMP2 was associated with higher grade gliomas. Patients with EMMPRIN+/MMP2+ expression had the lowest survival rate (p < 0.01). Based on these results, we conclude that EMMPRIN and MMP2 are expressed differently in normal brain and pediatric gliomas. The detection of their co-expression may facilitate the prediction of pediatric gliomas prognosis.
Gu
Jian
J
Department of Pediatrics, Taihe Hospital Affiliated with the Yunyang Medical College, Shiyan, Hubei, 442000, China.
Zhang
Che
C
Chen
Rongguang
R
Pan
Jun
J
Wang
Yong
Y
Ming
Meng
M
Gui
Weixing
W
Wang
Dabin
D
D001254:Astrocytoma / Q000378:metabolism* / Q000473:pathology; D051926:Basigin / Q000378:metabolism*; D001932:Brain Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D011379:Prognosis
C497886:BSG protein, human; D051926:Basigin; D020778:Matrix Metalloproteinase 2
Pathol Int. 2006 Jul;56(7):359-67
16792544
Am J Pathol. 2002 Apr;160(4):1215-21
11943706
Cancer Res. 2005 Apr 15;65(8):3193-9
15833850
Brain Pathol. 1993 Jul;3(3):255-68
8293185
Cancer. 2004 Nov 1;101(9):1994-2000
15372476
Cancer Res. 2001 Mar 1;61(5):2276-81
11280798
Oncogene. 2007 Aug 9;26(36):5229-37
17325663
Int J Cancer. 2006 Oct 15;119(8):1800-10
16721788
Cancer Res. 2007 May 1;67(9):4088-97
17483319
Cancer Immunol Immunother. 2008 Sep;57(9):1367-79
18273614
Int J Cancer. 2003 Sep 20;106(5):745-51
12866035
Am J Pathol. 2005 Jan;166(1):209-19
15632013
Int J Cancer. 2002 May 10;99(2):157-66
11979428
Br J Cancer. 1996 Jun;73(11):1401-8
8645587
Mol Cancer Res. 2005 Oct;3(10):541-51
16254188
Am J Pathol. 1996 Jul;149(1):273-82
8686751
Cancer Res. 2004 Feb 15;64(4):1229-32
14983875
Brain Pathol. 2007 Jul;17(3):276-81
17465990
Am J Pathol. 1999 Feb;154(2):417-28
10027400
Rev Recent Clin Trials. 2006 May;1(2):119-31
18473963
Cancer Gene Ther. 2003 Nov;10(11):823-32
14605668
Am J Pathol. 2001 Jun;158(6):1921-8
11395366
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Int J Cancer. 2003 Feb 20;103(5):647-51
12494473